Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycerophosphodiester phosphodiesterase domain-containing protein 2 (GDPD2)
- Target
- GDPD2
- Molecular classification
- Enzyme
01
Overview
Glycerophosphodiester phosphodiesterase domain-containing protein 2 (GDPD2) is a membrane-bound enzyme belonging to the glycerophosphodiester phosphodiesterase family. It functions at the cell surface as an extracellular phospholipase C, selectively hydrolyzing glycerophosphoinositol and lysophospholipids to produce inositol 1-phosphate and glycerol, thereby modulating lipid mediator balance. This catalytic activity is essential for processes such as osteoblast differentiation and growth, and GDPD2’s dosage alteration has been linked to neurodevelopmental disorders. While it is mainly characterized as an enzyme, its activity is relevant to signaling pathways and may impact reproductive traits, making it relevant as a potential therapeutic target and biomarker in disease contexts
- Other names
- GDE3Osteoblast differentiation promoting factorOBDPFFLJ20207Glycerophosphoinositol inositolphosphodiesterase GDPD2Glycerophosphodiester phosphodiesterase 3
02
Mechanism of action
Drugs or molecules that inhibit or activate GDPD2 would likely alter extracellular lipid mediator levels, potentially affecting cell morphology, differentiation, and signaling pathways involving lipid-modified receptors
03
Biological functions
Hydrolyzes glycerophosphoinositol to produce inositol 1-phosphate and glycerolModifies extracellular lipid signals by hydrolyzing lysophospholipids (such as lysophosphatidylinositol), affecting lipid mediator balanceAccelerates osteoblast differentiation and growthModulates actin cytoskeleton remodeling (by similarity)
04
Disease associations
Neurodevelopmental disordersCancerReproductive traits
05
Safety considerations
Potential disruption of bone formation, neurodevelopment, and reproductive processes due to GDPD2’s key roles in these functionsUnknown off-target effects with enzyme modulators since GDPD2 may have selectivity for certain glycerophosphoinositol substrates
06
Biomarkers
Expression levels of GDPD2 may serve as biomarkers for osteoblast differentiation, certain cancer states, and neurodevelopmental disorders due to its differential expression in these contexts
Beyond the preview
Go deeper on Glycerophosphodiester phosphodiesterase domain-containing protein 2 (GDPD2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycerophosphodiester phosphodiesterase domain-containing protein 2 (GDPD2).